OJMN  Vol.3 No.4 , October 2013
New Developments in Drug Therapy and Research of Cerebral Vasospasm
In this manuscript a comprehensive coverage of recent developments in the drug therapy of vasospasm while providing the background information that neuroscientists need to understand its rationale. The range of new agents available for treatment of cerebral vasospasm is expanding rapidly along with rapid advances in pharmacology and physiology that are uncovering the mechanisms of this disease. Although there are many publications for treatment of cerebral vaso-spasm, most are focusing on different aspects of vasospasm treatment and many have limited value due to insufficient quality. Moreover, the complexity of this, in many cases deleterious condition, is enormous and the information needed to understand drug effects is accordingly often not readily available in a single source. A number of pharmacological and medical therapies are currently in use or being investigated in an attempt to reverse cerebral vasospasm, but only a few have proven to be useful. Current research efforts promise the eventual production of new medical therapies. At last, recommendations for the use of different treatment stages based on currently available clinical data are provided.

Cite this paper
E. Archavlis, P. Ulrich and M. Nievas, "New Developments in Drug Therapy and Research of Cerebral Vasospasm," Open Journal of Modern Neurosurgery, Vol. 3 No. 4, 2013, pp. 72-93. doi: 10.4236/ojmn.2013.34016.
[1]   N. F. Kassell, T. Sasaki, A. R. Colohan, et al., “Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage,” Stroke, Vol. 16, No. 4, 1985, pp. 562-572. http://dx.doi.org/10.1161/01.STR.16.4.562

[2]   N. F. Kassell, J. C. Torner, E. C. Haley Jr., et al., “The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall Management Results,” Journal of Neurosurgery, Vol. 73, No. 1, 1990, pp. 18-36. http://dx.doi.org/10.3171/jns.1990.73.1.0018

[3]   K. Maeda, H. Kurita, T. Nakamura, et al., “Occurrence of Severe Vasospasm Following Intraventricular Hemorrhage from an Arteriovenous Malformation. Report of Two Cases,” Journal of Neurosurgery, Vol. 87, No. 3, 1997, pp. 436-439. http://dx.doi.org/10.3171/jns.1997.87.3.0436

[4]   M. N. Carvi y Nievas and E. Archavlis, “Atypical Causes of Nontraumatic Intracranial Subarachnoid Hemorrhage,” Clinical Neurology and Neurosurgery, Vol. 111, No. 4, 2009, pp. 354-358. http://dx.doi.org/10.1016/j.clineuro.2008.11.010

[5]   N. A. Martin, C. Doberstein, C. Zane, M. J. Caron, K. Thomas and D. P. Becker, “Posttraumatic Cerebral Arterial Spasm: Transcranial Doppler Ultrasound, Cerebral Blood Flow, and Angiographic Findings,” Journal of Neurosurgery, Vol. 77, No. 4, 1992, pp. 575-583. http://dx.doi.org/10.3171/jns.1992.77.4.0575

[6]   E. C. Raps, S. L. Galetta, M. Broderick and S. W. Atlas, “Delayed Peripartum Vasculopathy: Cerebral Eclampsia Revisited,” Annals of Neurology, Vol. 33, No. 2, 1993, pp. 222-225. http://dx.doi.org/10.1002/ana.410330215

[7]   A. A. Rabinstein, G. Lanzino, E. F. Wijdicks, “Multidisciplinary Management and Emerging Therapeutic Strategies in Aneurysmal Subarachnoid Haemorrhage,” Lancet Neurology, Vol. 9, No. 5, 2010, pp. 504-519. http://dx.doi.org/10.1016/S1474-4422(10)70087-9

[8]   O. Samuels, A. Webb, S. Culler, et al., “Impact of a Dedicated Neurocritical Care Team in Treating Patients with Aneurysmal Subarachnoid Hemorrhage,” Neurocritical Care, Vol. 14, No. 3, 2011, pp. 334-340. http://dx.doi.org/10.1007/s12028-011-9505-z

[9]   E. Archavlis and M. N. Carvi y Nievas, “Acute Management of Poor Condition Subarachnoid Hemorrhage Patients,” Vascular Health and Risk Management, Vol. 3, No. 6, 2007, pp. 1075-1082.

[10]   D. Castanares-Zapatero and P. Hantson, “Pharmacological Treatment of Delayed Cerebral Ischemia and Vasospasm in Subarachnoid Hemorrhage,” Annals of Intensive Care, Vol. 1, No. 1, 2011, p. 12. http://dx.doi.org/10.1186/2110-5820-1-12

[11]   S. Shirao, H. Yoneda, H. Ishihara, K. Kajiwara and M. Suzuki, “Survey Study Members of Japan Neurosurgical Society. A Proposed Definition of Symptomatic Vasospasm Based on Treatment of Cerebral Vasospasm after Subarachnoid Hemorrhage in Japan: Consensus 2009, a Project of the 25 Spasm Symposium,” Surgical Neurology International, Vol. 2, 2011, p. 74.

[12]   M. D. Vergouwen, “Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Vasospasm Versus Delayed Cerebral Ischemia as an Outcome Event in Clinical Trials and Observational Studies,” Neurocritical Care, Vol. 15, No. 2, 2011, pp. 308-311. http://dx.doi.org/10.1007/s12028-011-9586-8

[13]   M. M. Treggiari-Venzi, P. M. Suter and J. A. Romand, “Review of Medical Prevention of Vasospasm after Aneurysmal Subarachnoid Hemorrhage: A Problem of Neuro-intensive Care,” Neurosurgery, Vol. 48, No. 2, 2001, pp. 249-261. http://dx.doi.org/10.1227/00006123-200102000-00001

[14]   M. D. Vergouwen, D. Ilodigwe and R. L. Macdonald, “Cerebral Infarction after Sub-Arachnoid Hemorrhage Contributes to Poor Outcome by Vasospasm-Dependent and Independent Effects,” Stroke, Vol. 42, No. 4, 2011, pp. 924-929. http://dx.doi.org/10.1161/STROKEAHA.110.597914

[15]   F. A. Sehba, R. M. Pluta and J. H. Zhang, “Metamorphosis of Subarachnoid Hemorrhage Research: From Delayed Vasospasm to Early Brain Injury,” Molecular Neurobiology, Vol. 43, No. 1, 2011, pp. 27-40. http://dx.doi.org/10.1007/s12035-010-8155-z

[16]   J. P. Dreier, “The Role of Spreading Depression, Spreading Depolarization and Spreading Ischemia in Neurological Disease,” Nature Medicine, Vol. 17, No. 4, 2011, pp. 439-447. http://dx.doi.org/10.1038/nm.2333

[17]   L. Z. Leng, M. E. Fink and C. Iadecola, “Spreading Depolarization: A Possible New Culprit in the Delayed Cerebral Ischemia of Subarachnoid Hemorrhage,” Archives of Neurology, Vol. 68, No. 1, 2011, pp. 31-36. http://dx.doi.org/10.1001/archneurol.2010.226

[18]   C. Muroi, S. Mink, M. Seule, et al., “Monitoring of the Inflammatory Response after Aneurysmal Subarachnoid Haemorrhage in the Clinical Setting: Review of Literature and Report of Preliminary Clinical Experience,” Acta Neurochirurgica Supplement, Vol. 110, Pt. 1, 2011, pp. 191-196.

[19]   T. Nakura, K. Osuka, T. Inukai, et al., “Soluble gp130 Regulatess Interleukin-6 in Cerebrospinal Fluid after Subarachnoid Haemorrhage,” Journal of Neurology, Neurosurgery, and Psychiatry, Vol. 82, No. 9, 2011, pp. 952-954. http://dx.doi.org/10.1136/jnnp.2009.197244

[20]   A. Sarrafzadeh, F. Schlenk, C. Gericke and P. Vajkoczy, “Relevance of Cerebral Interleukin-6 after Aneurysmal Subarachnoid Hemorrhage,” Neurocritical Care, Vol. 13, No. 3, 2010, pp. 339-346. http://dx.doi.org/10.1007/s12028-010-9432-4

[21]   L. Edvinsson and G. K. Povlsen, “Late Cerebral Ischaemia after Subarachnoid Haemorrhage: Is Cerebrovascular Receptor Upregulation the Mechanism Behind?” Acta Physiologica, Vol. 203, No. 1, 2011, pp. 209-224. http://dx.doi.org/10.1111/j.1748-1716.2010.02227.x

[22]   R. W. Crowley, R. Medel, A. S. Dumont, et al., “Angiographic Vasospasm Is Strongly Correlated with Cerebral Infarction after Subarachnoid Hemorrhage,” Stroke, Vol. 42, No. 4, 2011, pp. 919-923. http://dx.doi.org/10.1161/STROKEAHA.110.597005

[23]   J. P. Kistler, R. M. Crowell, K. R. Davis, et al., “The Relation of Cerebral Vasospasm to the Extent and Location of Subarachnoid Blood Visualized by CT Scan: A Prospective Study,” Neurology, Vol. 33, No. 4, 1983, pp. 424-436. http://dx.doi.org/10.1212/WNL.33.4.424

[24]   C. M. Fisher, J. P. Kistler and J. M. Davis, “Relation of Cerebral Vasospasm to Subarachnoid Hemorrhage Visualized by Computerized Tomographic Scanning,” Neuro-surgery, Vol. 6, No. 1, 1980, pp. 1-9. http://dx.doi.org/10.1227/00006123-198001000-00001

[25]   M. D. Vergouwen, N. Etminan, D. Ilodigwe and R. L. Macdonald, “Lower Incidence of Cerebral Infarction Correlates with Improved Functional Outcome after Aneurysmal Subarachnoid Hemorrhage,” Journal of Cerebral Blood Flow & Metabolism, Vol. 31, No. 7, 2011, pp. 1545-1553. http://dx.doi.org/10.1038/jcbfm.2011.56

[26]   J. Sharkey, S. P. Butcher and J. S. Kelly, “Endothelin-1 Induced Middle Cerebral Artery Occlusion: Pathological Consequences and Neuroprotective Effects of MK801,” Journal of the Autonomic Nervous System, Vol. 49, 1994, pp. S177-S185. http://dx.doi.org/10.1016/0165-1838(94)90109-0

[27]   P. Gaetani, R. Baena, G. Grignani, G. Spanu, L. Pacchiarini and P. Paoletti, “Endothelin and Aneurysmal Subarachnoid Haemorrhage: A Study of Subarachnoid Cisternal Cerebrospinal Fluid,” Journal of Neurology, Neurosurgery, and Psychiatry, Vol. 57, No. 1, 1994, pp. 66-72. http://dx.doi.org/10.1136/jnnp.57.1.66

[28]   J. Hansen-Schwartz, S. Ansar and L. Edvinsson, “Cerebral Vasoconstriction after Subarachnoid Hemorrhage— Role of Changes in Vascular Receptor Phenotype,” Frontiers in Bioscience, Vol. 13, 2008, pp. 2160-2164.

[29]   J. Hansen-Schwartz, N. L. Hoel, M. Zhou, C. B. Xu, N. A. Svendgaard and L. Edvinsson, “Subarachnoid Hemorrhage Enhances Endothelin Receptor Expression and Function in Rat Cerebral Arteries,” Neurosurgery, Vol. 52, No. 5, 2003, pp. 1188-1194. http://dx.doi.org/10.1227/01.NEU.0000058467.82442.64

[30]   L. Edvinsson, “Cerebrovascular Endothelin Receptor Up-regulation in Cerebral Ischemia,” Current Vascular Pharmacology, Vol. 7, No. 1, 2009, pp. 26-33. http://dx.doi.org/10.2174/157016109787354178

[31]   R. D. Rothoerl and F. Ringel, “Molecular Mechanisms of Cerebral Vasospasm Following Aneurysmal SAH,” Neurological Research, Vol. 29, No. 7, 2007, pp. 636-642. http://dx.doi.org/10.1179/016164107X240224

[32]   Y. Hirata, H. Yoshimi, S. Takaichi, M. Yanagisawa and T. Masaki, “Binding and Receptor Down-Regulation of a Novel Vasoconstrictor Endothelin in Cultured Rat Vascular Smooth Muscle Cells,” FEBS Letters, Vol. 239, No. 1, 1988, pp. 13-17. http://dx.doi.org/10.1016/0014-5793(88)80536-2

[33]   C. Lan, D. Das, A. Wloskowicz and B. Vollrath, “Endothelin-1 Modulates Hemoglobin-Mediated Signaling in Cerebrovascular Smooth Muscle via RhoA/Rho Kinase and Protein Kinase C,” American Journal of Physiology-Heart and Circulatory Physiology, Vol. 286, No. 1, 2004, pp. H165-H173. http://dx.doi.org/10.1152/ajpheart.00664.2003

[34]   M. E. Grassie, L. D. Moffat, M. P. Walsh and J. A. Mac-Donald, “The Myosin Phosphatase Targeting Protein (MYPT) Family: A Regulated Mechanism for Achieving Substrate Specificity of the Catalytic Subunit of Protein Phosphatase Type 1δ,” Archives of Biochemistry and Biophysics, Vol. 510, No. 2, 2011, pp. 147-159. http://dx.doi.org/10.1016/j.abb.2011.01.018

[35]   L. Miao, Y. Dai and J. Zhang, “Mechanism of RhoA/Rho Kinase Activation in Endothelin-1-Induced Contraction in Rabbit Basilar Artery,” American Journal of Physiology—Heart and Circulatory Physiology, Vol. 283, No. 3, 2002, pp. H983-H989.

[36]   Y. Kikkawa, S. Matsuo, K. Kameda, M. Hirano, A. Nakamizo, T. Sasaki and K. Hirano, “Mechanisms Underlying Potentiation of Endothelin-1-Induced Myofilament Ca2+ Sensitization after Subarachnoid Hemorrhage,” Journal of Cerebral Blood Flow & Metabolism, Vol. 32, No. 2, 2012, pp. 341-352. http://dx.doi.org/10.1038/jcbfm.2011.132

[37]   K. Obara, S. Nishizawa, M. Koide, K. Nozawa, A. Mitate, T. Ishikawa and K. Nakayama, “Interactive Role of Protein Kinase C-Delta with Rho-Kinase in the Development of Cerebral Vasospasm in a Canine Two-Hemorrhage Model,” Journal of Vascular Research, Vol. 42, No. 1, 2005, pp. 67-76. http://dx.doi.org/10.1159/000083093

[38]   M. P. Walsh, “Vascular Smooth Muscle Myosin Light Chain Diphosphorylation: Mechanism, Function, and Pathological Implications,” IUBMB Life, Vol. 63, No. 11, 2011, pp. 987-1000. http://dx.doi.org/10.1002/iub.527

[39]   C. Sutherland and M. P. Walsh, “Myosin Regulatory Light Chain Diphosphorylation Slows Relaxation of Arterial Smooth Muscle,” Journal of Biological Chemistry, Vol. 287, No. 29, 2012, pp. 24064-24076. http://dx.doi.org/10.1074/jbc.M112.371609

[40]   B. G. Allen and M. P. Walsh, “The Biochemical Basis of the Regulation of Smooth-Muscle Contraction,” Trends in Biochemical Sciences, Vol. 19, No. 9, 1994, pp. 362-368. http://dx.doi.org/10.1016/0968-0004(94)90112-0

[41]   A. P. Somlyo and A. V. Somlyo, “Ca2+ Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase,” Physiological Reviews, Vol. 83, No. 4, 2003, pp. 1325-1358.

[42]   F. Hofmann, “The Biology of Cyclic GMP-Dependent Protein Kinases,” Journal of Biological Chemistry, Vol. 280, No. 1, 2005, pp. 1-4.

[43]   O. Guney, F. Erdi, H. Esen, A. Kiyici and Y. Kocaogullar, “N-Acetylcysteine Prevents Vasospasm after Subarachnoid Hemorrhage,” Surgical Neurology, Vol. 73, No. 1, 2010, pp. 42-49.

[44]   A. Munakata, H. Ohkuma and N. Shimamura, “Effect of a Free Radical Scavenger, Edaravone, on Free Radical Reactions: Related Signal Transduction and Cerebral Vasospasm in the Rabbit Subarachnoid Hemorrhage Model,” Acta Neurochirurgica Supplement, Vol. 110. No. 2, 2011, pp. 17-22.

[45]   K. Nakamura, Y. Koga, H. Sakai, K. Homma and M. Ikebe, “cGMP-Dependent Relaxation of Smooth Muscle Is Coupled with the Change in the Phosphorylation of Myosin Phosphatase,” Circulation Research, Vol. 101, No. 7, 2007, pp. 712-722. http://dx.doi.org/10.1161/CIRCRESAHA.107.153981

[46]   F. Kehl, L. Cambj-Sapunar, K. G. Maier, N. Miyata, S. Kametani, H. Okamoto, et al., “20-HETE Contributes to the Acute Fall in Cerebral Blood Flow after Subarachnoid Hemorrhage in the Rat,” American Journal of Physiology—Heart and Circulatory Physiology, Vol. 282, No. 4, 2002, pp. H1556-H1565.

[47]   P. Pacher, J. S. Beckman and L. Liaudet, “Nitric Oxide and Peroxynitrite in Health and Disease,” Physiological Reviews, Vol. 87, No. 1, 2007, pp. 315-424. http://dx.doi.org/10.1152/physrev.00029.2006

[48]   D. E. Kim, Y. S. Suh, M. S. Lee, K. Y. Kim, J. H. Lee, H. S. Lee, et al., “Vascular NAD(P)H Oxidase Triggers Delayed Cerebral Vasospasm after Subarachnoid Hemorrhage in Rats,” Stroke, Vol. 33, No. 11, 2002, pp. 2687-2691. http://dx.doi.org/10.1161/01.STR.0000033071.99143.9E

[49]   J. S. Zheng, R. Y. Zhan, S. S. Zheng, Y. Q. Zhou, Y. Tong and S. Wan, “Inhibition of NADPH Oxidase Attenuates Vasospasm after Experimental Subarachnoid Hemorrhage in Rats,” Stroke, Vol. 36, No. 5, 2005, pp. 1059-1064.

[50]   C. Zhou, M. Yamaguchi, G. Kusaka, C. Schonholz, A. Nanda and J. H. Zhang, “Caspase Inhibitors Prevent Endothelial Apoptosis and Cerebral Vasospasm in Dog Model of Experimental Subarachnoid Hemorrhage,” Journal of Cerebral Blood Flow & Metabolism, Vol. 24, No. 4, 2004, pp. 419-431. http://dx.doi.org/10.1097/00004647-200404000-00007

[51]   A. Y. Zubkov, K. Ogihara, D. H. Bernanke, A. D. Parent and J. Zhang, “Apoptosis of Endothelial Cells in Vessels Affected by Cerebral Vasospasm,” Surgical Neurology, Vol. 53, No. 3, 2000, pp. 260-266. http://dx.doi.org/10.1016/S0090-3019(99)00187-1

[52]   H. Kimura, I. Gules, T. Meguro and J. H. Zhang, “Cytotoxicity of Cytokines in Cerebral Microvascular Endothelial Cell,” Brain Research, Vol. 990, No. 1-2, 2003, pp. 148-156. http://dx.doi.org/10.1016/S0006-8993(03)03450-4

[53]   K. Iseda, S. Ono, K. Onoda, M. Satoh, H. Manabe, M. Nishiguchi, et al., “Antivasospastic and Antiinflammatory Effects of Caspase Inhibitor in Experimental Subarachnoid Hemorrhage,” Journal of Neurosurgery, Vol. 107, No. 1, 2007, pp. 128-135. http://dx.doi.org/10.3171/JNS-07/07/0128

[54]   R. M. Pluta, “Dysfunction of Nitric Oxide Synthases as a Cause and Therapeutic Target in Delayed Cerebral Vasospasm after SAH,” Acta Neurochirurgica Supplement, Vol. 104, 2008, pp. 139-147.

[55]   A. S. Dumont, R. J. Dumont, M. M. Chow, et al., “Cerebral Vasospasm after Subarachnoid Hemorrhage: Putative Role of Inflammation,” Neurosurgery, Vol. 53, No. 1, 2003, pp. 123-133. http://dx.doi.org/10.1227/01.NEU.0000068863.37133.9E

[56]   T. Sozen, R. Tsuchiyama, Y. Hasegawa, et al., “Role of Interleukin-1beta in Early Brain Injury after Subarachnoid Hemorrhage in Mice,” Stroke, Vol. 40, No. 7, 2009, pp. 2519-2525. http://dx.doi.org/10.1161/STROKEAHA.109.549592

[57]   K. Fassbender, B. Hodapp, S. Rossol, et al., “Endothelin-1 in Subarachnoid Hemorrhage: An Acute-Phase Reactant Produced by Cerebrospinal Fluid Leukocytes,” Stroke, Vol. 31, No. 12, 2000, pp. 2971-2975. http://dx.doi.org/10.1161/01.STR.31.12.2971

[58]   H. Takeuchi, M. Tanabe, H. Okamoto and M. Yamazaki, “Effects of Thromboxane Synthetase Inhibitor (RS-5186) on Experimentally-Induced Cerebral Vasospasm,” Neurological Research, Vol. 21, No. 5, 1999, pp. 513-516.

[59]   S. Satoh, Y. Suzuki, T. Harada, et al., “The Role of Platelets in the Development of Cerebral Vasospasm,” Brain Research Bulletin, Vol. 27, No. 5, 1991, pp. 663-668. http://dx.doi.org/10.1016/0361-9230(91)90042-I

[60]   G. F. Prunell, N. A. Svendgaard, K. Alkass and T. Mathiesen, “Inflammation in the Brain after Experimental Subarachnoid—Hemorrhage,” Neurosurgery, Vol. 56, No. 5, 2005, pp. 1082-1092.

[61]   M. Bavbek, R. Polin, A. L. Kwan, A. S. Arthur, N. F. Kassell and K. S. Lee, “Monoclonal Antibodies against ICAM-1 and CD18 Attenuate Cerebral Vasospasm after Experimental Subarachnoid Hemorrhage in Rabbits,” Stroke, Vol. 29, No. 9, 1998, pp. 1930-1935. http://dx.doi.org/10.1161/01.STR.29.9.1930

[62]   R. S. Polin, M. Bavbek, M. E. Shaffrey, et al., “Detection of Soluble E-Selectin, ICAM-1, VCAM-1, and L-Selectin in the Cerebrospinal Fluid of Patients after Subarachnoid Hemorrhage,” Journal of Neurosurgery, Vol. 89, No. 4, 1998, pp. 559-567. http://dx.doi.org/10.3171/jns.1998.89.4.0559

[63]   J. Cahill, J. W. Calvert, I. Solaroglu and J. H. Zhang, “Vasospasm and p53-Induced Apoptosis in an Experimental Model of Subarachnoid Hemorrhage,” Stroke, Vol. 37, No. 7, 2006, pp. 1868-1874. http://dx.doi.org/10.1161/01.STR.0000226995.27230.96

[64]   E. Kozniewska, R. Michalik, J. Rafalowska, et al., “Mechanisms of Vascular Dysfunction after Subarachnoid Hemorrhage,” Journal of Physiology and Pharmacology, Vol. 57, Suppl. 11, 2006, pp. 145-160.

[65]   E. Grote and W. Hassler, “The Critical First Minutes after Subarachnoid Hemorrhage,” Neurosurgery, Vol. 22, No. 4, 1988, pp. 654-661. http://dx.doi.org/10.1227/00006123-198804000-00006

[66]   W. E. Hoffman, P. Wheeler, G. Edelman, F. T. Charbel, N. J. Torres and J. I. Ausman, “Hypoxic Brain Tissue Following Subarachnoid Hemorrhage,” Anesthesiology, Vol. 92, No. 2, 2000, pp. 442-446. http://dx.doi.org/10.1097/00000542-200002000-00026

[67]   T. Hishikawa, S. Ono, T. Ogawa, K. Tokunaga, K. Sugiu and I. Date, “Effects of Deferoxamine-Activated Hypoxia-Inducible Factor-1 on the Brainstem after Subarachnoid Hemorrhage in Rats,” Neurosurgery, Vol. 62, No. 1, 2008, pp. 232-240. http://dx.doi.org/10.1227/01.NEU.0000311082.88766.33

[68]   G. L. Semenza, “Regulation of Oxygen Homeostasis by Hypoxia-Inducible Factor 1,” Physiology Bethesda, Vol. 24, 2009, pp. 97-106. http://dx.doi.org/10.1152/physiol.00045.2008

[69]   R. Schmidt-Kastner, C. Aguirre-Chen, T. Kietzmann, I. Saul, R. Busto and M. D. Ginsberg, “Nuclear Localization of the Hypoxia-Regulated Pro-Apoptotic Protein BNIP3 after Global Brain Ischemia in the Rat Hippo-campus,” Brain Research, Vol. 1001, No. 1-2, 2004, pp. 133-142. http://dx.doi.org/10.1016/j.brainres.2003.11.065

[70]   H. Jeon, J. Ai, M. Sabri, et al., “Neurological and Neurobehavioral Assessment of Experimental Subarachnoid Hemorrhage,” BMC Neuroscience, Vol. 10, 2009, p. 103. http://dx.doi.org/10.1186/1471-2202-10-103

[71]   J. Cahill, J. W. Calvert, S. Marcantonio and J. H. Zhang, “p53 May Play an Orchestrating Role in Apoptotic Cell Death after Experimental Subarachnoid Hemorrhage,” Neurosurgery, Vol. 60, No. 3, 2007, pp. 531-545. http://dx.doi.org/10.1227/01.NEU.0000249287.99878.9B

[72]   J. Yan, C. Chen, J. Lei, et al., “2-Methoxyestradiol Reduces Cerebral Vasospasm after 48 Hours of Experimental Subarachnoid Hemorrhage in Rats,” Experimental Neurology, Vol. 202, No. 2, 2006, pp. 348-356. http://dx.doi.org/10.1016/j.expneurol.2006.06.009

[73]   J. D. Pearl and R. L. Macdonald, “Vasospasm after Aneurysmal Subarachnoid Hemorrhage: Need for Further Study,” Acta Neurochirurgica Supplement, Vol. 105, 2008, pp. 207-210. http://dx.doi.org/10.1007/978-3-211-09469-3_39

[74]   J. P. Dreier, S. Major, A. Manning, et al., “Cortical Spreading Ischaemia Is a Novel Process Involved in Ischaemic Damage in Patients with Aneurysmal Subarachnoid Haemorrhage,” Brain, Vol. 132, 2009, pp. 1866-1881. http://dx.doi.org/10.1093/brain/awp102

[75]   J. Kleeberg, G. C. Petzold, S. Major, U. Dirnagl and J. P. Dreier, “ET-1 Induces Cortical Spreading Depression via Activation of the ETA Receptor/Phospholipase C Pathway in Vivo,” American Journal of Physiology—Heart and Circulatory Physiology, Vol. 286, No. 4, 2004, pp. H1339-H1346. http://dx.doi.org/10.1152/ajpheart.00227.2003

[76]   M. Balestrino, J. Young and P. Aitken, “Block of Na+, K+ ATPase with Ouabain Induces Spreading Depression-Like Depolarization in Hippocampal Slices,” Brain Research, Vol. 838, No. 1-2, 1999, pp. 37-44. http://dx.doi.org/10.1016/S0006-8993(99)01674-1

[77]   K. Yufu, T. Itoh, R. Edamatsu, A. Mori and M. Hirakawa, “Effect of Hyperbaric Oxygenation on the Na+, K+-AT-Pase and Membrane Fluidity of Cerebrocortical Membranes after Experimental Subarachnoid Hemorrhage,” Neurochemical Research, Vol. 18, No. 9, 1993, pp. 1033-1039. http://dx.doi.org/10.1007/BF00966765

[78]   G. D. Murray, “Surgical Bleeding and Calcium Antagonists. British Aneurysm Nimodipine Trial Reported Improved Clinical Outcome with Nimodipine,” British Medical Journal, Vol. 311, No. 7001, 1995, pp. 388-389. http://dx.doi.org/10.1136/bmj.311.7001.388c

[79]   J. D. Pickard, G. D. Murray, R. Illingworth, M. D. Shaw, G. M. Teasdale, P. M. Foy, et al., “Effect of Oral Nimodipine on Cerebral Infarction and Outcome after subarachnoid Haemorrhage: British Aneurysm Nimodipine Trial,” British Medical Journal, Vol. 298, 1989, pp. 636-642. http://dx.doi.org/10.1136/bmj.298.6674.636

[80]   F. G. Barker II and C. S. Ogilvy, “Efficacy of Prophylactic Nimodipine for Delayed Ischemic Deficit after Subarachnoid Hemorrhage: A Metaanalysis,” Journal of Neurosurgery, Vol. 84, No. 3, 1996, pp. 405-414. http://dx.doi.org/10.3171/jns.1996.84.3.0405

[81]   P. Karinen, P. Koivukangas, A. Ohinmaa, J. Koivukangas and J. Ohman, “Cost-Effectiveness Analysis of Nimodipine Treatment after Aneurysmal Subarachnoid Hemorrhage and Surgery,” Neurosurgery, Vol. 45, No. 4, 1999, pp. 780-785. http://dx.doi.org/10.1097/00006123-199910000-00009

[82]   F. A. Schanne, A. B. Kane, E. E. Young and J. L. Farber, “Calcium Dependence of Toxic Cell Death: A Final Common Pathway,” Science, Vol. 206, No. 4419, 1979, pp. 700-702.

[83]   J. Dale, K. H. Landmark and E. Myhre, “The Effects of Nifedipine, a Calcium Antagonist, on Platelet Function,” American Heart Journal, Vol. 105, No. 1, 1983, pp. 103-105. http://dx.doi.org/10.1016/0002-8703(83)90285-5

[84]   L. M. Auer, “Pial Arterial Vasodilation by Intravenous Nimodipine in Cats,” Arzneimittelforschung, Vol. 31, No. 9, 1981, pp. 1423-1425.

[85]   N. F. Kassell, E. C. Haley Jr., C. Apperson-Hansen and W. M. Alves, “Randomized, Double-Blind, Vehicle-Controlled Trial of Tirilazad Mesylate in Patients with Aneurysmal Subarachnoid Hemorrhage: A Cooperative Study in Europe, Australia, and New Zealand,” Journal of Neurosurgery, Vol. 84, No. 2, 1996, pp. 221-228. http://dx.doi.org/10.3171/jns.1996.84.2.0221

[86]   A Munakata, H Ohkuma and N. Shimamura, “Effect of a Free Radical Scavenger, Edaravone, on Free Radical Reactions: Related Signal Transduction and Cerebral Vasospasm in the Rabbit Subarachnoid Hemorrhage Model,” Acta Neurochirurgica Supplement, Vol. 110, 2011, pp. 17-22.

[87]   D. M. Pollock, T. L. Keith and R. F. Highsmith, “Endothelin Receptors and Calcium Signaling,” The FASEB Journal, Vol. 9, No. 12, 1995, pp. 1196-1204.

[88]   R. L. Macdonald, R. T. Higashida, E. Keller, et al., “Clazosentan, an Endothelin Receptor Antagonist, in Patients with Aneurysmal Subarachnoid Haemorrhage Undergoing Surgical Clipping: A randomised, Double-Blind, Placebo-Controlled Phase 3 Trial (CONSCIOUS-2),” The Lancet Neurology, Vol. 10, No. 7, 2011, pp. 618-625. http://dx.doi.org/10.1016/S1474-4422(11)70108-9

[89]   R. L. Macdonald, R. T. Higashida, E. Keller, et al., “Preventing Vasospasm Improves Outcome after Aneurysmal Subarachnoid Hemorrhage: Rationale and Design of CONSCIOUS-2 and CONSCIOUS-3 Trials,” Neurocritical Care, Vol. 13, No. 3, 2010, pp. 416-427. http://dx.doi.org/10.1007/s12028-010-9433-3

[90]   T. Kerz, S. Boor, C. Beyer, S. Welschehold, A. Schuessler and J. Oertel, “Effect of Intraarterial Papaverine or Nimodipine on Vessel Diameter in Patients with Cerebral Vasospasm after Subarachnoid Hemorrhage,” British Journal of Neurosurgery, Vol. 26, No. 4, 2012, pp. 517-524. http://dx.doi.org/10.3109/02688697.2011.650737

[91]   M. Lannes, J. Teitelbaum, M. del Pilar Cortés, M. Cardoso and M. Angle, “Milrinone and Homeostasis to Treat Cerebral Vasospasm Associated With Subarachnoid Hemorrhage: The Montreal Neurological Hospital Protocol,” Neurocritical Care, Vol. 16, No. 3, 2012, pp. 354-362. http://dx.doi.org/10.1007/s12028-012-9701-5

[92]   A. Baumann, A. L. Derelle, P. M. Mertes and G. Audibert, “Seeking New Approaches: Milrinone in the Treatment of Cerebral Vasospasm,” Neurocritical Care, Vol. 16, No. 3, 2012, pp. 351-353. http://dx.doi.org/10.1007/s12028-012-9718-9

[93]   M. Yamaguchi, C. Zhou, A. Nanda and J. H. Zhang, “Ras Protein Contributes to Cerebral Vasospasm in a Canine Double-Hemorrhage Model,” Stroke, Vol. 35, No. 7, 2004, pp. 1750-1755. http://dx.doi.org/10.1161/01.STR.0000129898.68350.9f

[94]   C. Thome, M. Seiz, G. A. Schubert, et al., “Nicardipine Pellets for the Prevention of Cerebral Vasospasm,” Acta Neurochirurgica Supplement, Vol. 110, 2011, pp. 209-211.

[95]   H. Kasuya, “Clinical Trial of Nicardipine Prolonged-Release Implants for Preventing Cerebral Vasospasm: Multicenter Cooperative Study in Tokyo,” Acta Neurochirurgica Supplement, Vol. 110, 2011, pp. 165-167.

[96]   M. Barth, P. Pena, M. Seiz, et al., “Feasibility of Intraventricular Nicardipine Prolonged Release Implants in Patients Following Aneurysmal Subarachnoid Haemorrhage,” British Journal of Neurosurgery, Vol. 25, No. 6, 2011, pp. 677-683. http://dx.doi.org/10.3109/02688697.2010.548878

[97]   M. M. Treggiari, J. A. Romand, J. B. Martin, A. Reverdin, D. A. Rüfenacht and N. de Tribolet, “Cervical sympathetic Block to Reverse Delayed Ischemic Neurological Deficits after Aneurysmal Subarachnoid Hemorrhage,” Stroke, Vol. 34, No. 4, 2003, pp. 961-967. http://dx.doi.org/10.1161/01.STR.0000060893.72098.80

[98]   Y. Wu, K. Tang, R. Q. Huang, Z. Zhuang, H. L. Cheng, H. X. Yin and J. X. Shi, “Therapeutic Potential of peroxisome Proliferator-Activated Receptor γ Agonist Rosiglitazone in Cerebral Vasospasm after a Rat Experimental Subarachnoid Hemorrhage Model,” Journal of the Neurological Sciences, Vol. 305, No. 1-2, 2011, pp. 85-91. http://dx.doi.org/10.1016/j.jns.2011.03.006

[99]   R. Sercombe, Y. R. Dinh and P. Gomis, “Cerebrovascular Inflammation Following Subarachnoid Hemorrhage,” Japanese Journal of Pharmacology, Vol. 88, No. 3, 2002, pp. 227-249.

[100]   A. R. Fathi, K. D. Bakhtian and R. M. Pluta, “The Role of Nitric Oxide Donors in Treating Cerebral Vasospasm after Subarachnoid Hemorrhage,” Acta Neurochirurgica Supplement, Vol. 110, 2011, pp. 93-97.

[101]   A. R. Fathi, R. M. Pluta, K. D. Bakhtian, et al., “Reversal of Cerebral Vasospasm via Intravenous Sodium Nitrite after Subarachnoid Hemorrhage in Primates,” Journal of Neurosurgery, Vol. 115, No. 6, 2011, pp. 1213-1220. http://dx.doi.org/10.3171/2011.7.JNS11390

[102]   R. M. Pluta, E. H. Oldfield, K. D. Bakhtian, et al., “Safety and Feasibility of Long-Term Intravenous Sodium Nitrite Infusion in Healthy Volunteers,” PLoS One, Vol. 6, No. 1, 2011, Article ID: e14504. http://dx.doi.org/10.1371/journal.pone.0014504

[103]   K. Satoh, Y. Fukumoto and H. Shimokawa, “Rho-Kinase: Important New Therapeutic Target in Cardiovascular Diseases,” American Journal of Physiology—Heart and Circulatory Physiology, Vol. 301, No. 2, 2011, pp. H287-H296. http://dx.doi.org/10.1152/ajpheart.00327.2011

[104]   K. Ito, Y. Hirooka, K. Sakai, T. Kishi, K. Kaibuchi, H. Shimokawa and A. Takeshita, “Rho/Rho-Kinase Pathway in Brain Stem Contributes to Blood Pressure Regulation via Sympathetic Nervous System: Possible Involvement in Neural Mechanisms of Hypertension,” Circulation Research, Vol. 92, No. 12, 2003, pp. 1337-1343. http://dx.doi.org/10.1161/01.RES.0000079941.59846.D4

[105]   T. Zoerle, D. C. Ilodigwe, H. Wan, K. Lakovic, M. Sabri, J. Ai and R. L. Macdonald, “Pharmacologic Reduction of Angiographic Vasospasm in Experimental Subarachnoid Hemorrhage: Systematic Review and Meta-Analysis,” Journal of Cerebral Blood Flow & Metabolism, Vol. 32, No. 9, 2012, pp. 1645-1658. http://dx.doi.org/10.1038/jcbfm.2012.57

[106]   S. Satoh, M. Takayasu, K. Kawasaki, I. Ikegaki, A. Hitomi, K. Yano, M. Shibuya and T. Asano, “Antivasospastic Effects of Hydroxyfasudil, a Rho-Kinase Inhibitor, after Subarachnoid Hemorrhage,” Journal of Pharmacological Sciences, Vol. 118, No. 1, 2012, pp. 92-98. http://dx.doi.org/10.1254/jphs.11075FP

[107]   G. J. Velat, M. M. Kimball, J. D. Mocco and B. L. Hoh, “Vasospasm after Aneurysmal Subarachnoid Hemorrhage: Review of Randomized Controlled Trials and Meta-Analyses in the Literature,” World Neurosurgery, Vol. 76, No. 5, 2011, pp. 446-454. http://dx.doi.org/10.1016/j.wneu.2011.02.030

[108]   J. Zhao, D. Zhou, J. Guo, Z. Ren, L. Zhou, S. Wang, Y. Zhang, B. Xu, K. Zhao, R. Wang, Y. Mao, B. Xu, X. Zhang; Fasudil Aneurysmal Subarachnoid Hemorrhage Study Group, “Efficacy and Safety of Fasudil in Patients with Subarachnoid Hemorrhage: Final Results of a randomized Trial of Fasudil versus Nimodipine,” Neurologia Medico-Chirurgica (Tokyo), Vol. 51, No. 10, 2011, pp. 679-683. http://dx.doi.org/10.2176/nmc.51.679

[109]   T. Nakamura, T. Matsui, A. Hosono, A. Okano, N. Fujisawa, T. Tsuchiya, M. Indo, Y. Suzuki, S. Oya and H. S. Chang, “Beneficial Effect of Selective Intra-Arterial Infusion of Fasudil Hydrochloride as a Treatment of Symptomatic Vasospasm Following SAH,” Acta Neurochirurgica Supplement, Vol. 115, 2013, pp. 81-85.

[110]   G. J. Liu, Z. J. Wang, Y. F. Wang, L. L. Xu, X. L. Wang, Y. Liu, G. J. Luo, G. H. He and Y. J. Zeng, “Systematic Assessment and Meta-Analysis of the Efficacy and Safety of Fasudil in the Treatment of Cerebral Vasospasm in Patients with Subarachnoid Hemorrhage,” European Journal of Clinical Pharmacology, Vol. 68, No. 2, 2012, pp. 131-139. http://dx.doi.org/10.1007/s00228-011-1100-x

[111]   S. Wolf, “Routine Management of Volume Status after Aneurysmal Subarachnoid Hemorrhage,” Neurocritical Care, Vol. 15, No. 2, 2011, pp. 275-280. http://dx.doi.org/10.1007/s12028-011-9593-9

[112]   M. N. Diringer, T. P. Bleck, J. Claude Hemphill 3rd, et al., “Critical Care Management of Patients Following Aneurysmal Subarachnoid Hemorrhage: Recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference,” Neurocritical Care, Vol. 15, No. 2, 2011, pp. 211-240. http://dx.doi.org/10.1007/s12028-011-9605-9

[113]   P. Chittiboina, S. Conrad, P. McCarthy, et al., “The Evolving Role of Hemodilution in Treatment of Cerebral Vasospasm: A Historical Perspective,” World Neurosurgery, Vol. 75, No. 5-6, 2011, pp. 660-664. http://dx.doi.org/10.1016/j.wneu.2011.02.019

[114]   A. M. Naidech, A. Shaibani, R. K. Garg, et al., “Prospective, Randomized Trial of Higher Goal Hemoglobin after Subarachnoid Hemorrhage,” Neurocritical Care, Vol. 13, No. 3, 2010, pp. 313-320. http://dx.doi.org/10.1007/s12028-010-9424-4

[115]   G. Appelboom, D. Strozyk, B. Y. Hwang, et al., “Bedside Use of a Dual Aortic Balloon Occlusion for the Treatment of Cerebral Vasospasm,” Neurocritical Care, Vol. 13, No. 3, 2010, 385-388. http://dx.doi.org/10.1007/s12028-010-9442-2

[116]   T. Mori, Y. Katayama, T. Igarashi, N. Moro, J. Kojima and T. Hirayama, “Is the Circulating Plasma Volume Sufficiently Maintained? Fluid Management of an Aneurysmal Subarachnoid Hemorrhage in the Acute Phase,” Neurological Research, Vol. 34, No. 10, 2012, pp. 1016-1019. http://dx.doi.org/10.1179/1743132812Y.0000000093

[117]   L. T. Iseri and J. H. French, “Magnesium: Nature’s Physiologic Calcium Blocker,” American Heart Journal, Vol. 108, No. 1, 1984, pp. 188-193. http://dx.doi.org/10.1016/0002-8703(84)90572-6

[118]   J. I. Suarez, “Magnesium Sulfate Administration in Subarachnoid Hemorrhage,” Neurocritical Care, Vol. 15, No. 2, 2011, pp. 302-307. http://dx.doi.org/10.1007/s12028-011-9603-y

[119]   G. K. Wong, W. S. Poon, M. T. Chan, et al., “Intravenous Magnesium Sulphate for Aneurysmal Subarachnoid Hemorrhage (IMASH): A Randomized, Double-Blinded, Placebo-Controlled, Multicenter Phase III Trial,” Stroke, Vol. 41, No. 5, 2010, pp. 921-926. http://dx.doi.org/10.1161/STROKEAHA.109.571125

[120]   M. D. Vergouwen, “Magnesium Sulfate for Aneurysmal Subarachnoid Hemorrhage: The End of the Road or More Trials?” Critical Care, Vol. 15, No. 2, 2011, p. 140. http://dx.doi.org/10.1186/cc10055

[121]   K. Mori, T. Yamamoto, M. Miyazaki, et al., “Optimal Cerebrospinal Fluid Magnesium Ion Concentration for Vasodilatory Effect and Duration after Intracisternal Injection of Magnesium Sulfate Solution in a Canine Subarachnoid Hemorrhage Model,” Journal of Neurosurgery, Vol. 114, No. 4, 2011, pp. 1168-1175. http://dx.doi.org/10.3171/2010.10.JNS10866

[122]   M. Y. Tseng, “Summary of Evidence on Immediate Statins Therapy Following Aneurysmal Subarachnoid Hemorrhage,” Neurocritical Care, Vol. 15, No. 2, 2011, pp. 298-301. http://dx.doi.org/10.1007/s12028-011-9596-6

[123]   K. K. Mukherjee, S. K. Singh, V. K. Khosla, S. Mohindra and P. Salunke, “Safety and Efficacy of Sildenafil Citrate in Reversal of Cerebral Vasospasm: A Feasibility Study,” Surgical Neurology International, Vol. 3, 2012, p. 3. http://dx.doi.org/10.4103/2152-7806.92164

[124]   C. Kruuse, S. Gupta, E. Nilsson, L. Kruse and L. Edvinsson, “Differential Vasoactive Effects of Sildenafil and Tadalafil on Cerebral Arteries,” European Journal of Pharmacology, Vol. 674, No. 2-3, 2012, pp. 345-351. http://dx.doi.org/10.1016/j.ejphar.2011.10.037

[125]   J. Bardutzky, J. Witsch, E. Juttler, et al., “EARLYDRAIN-Outcome after Early Lumbar CSF-Drainage in Aneurysmal Subarachnoid Hemorrhage: Study Protocol for a Randomized Controlled Trial,” Trials, Vol. 12, 2011, p. 203. http://dx.doi.org/10.1186/1745-6215-12-203

[126]   R. J. Komotar, D. K. Hahn, G. H. Kim, et al., “Efficacy of Lamina Terminalis Fenestration in Reducing Shunt-Dependent Hydrocephalus Following Aneurysmal Subarachnoid Hemorrhage: A Systematic Review,” Journal of Neurosurgery, Vol. 111, No. 1, 2009, pp. 147-154. http://dx.doi.org/10.3171/2009.1.JNS0821

[127]   D. C. Widenka, S. Wolf, L. Schurer, D. V. Plev and C. B. Lumenta, “Factors Leading to Hydrocephalus after Aneurysmal Subarachnoid Hemorrhage,” Neurologia i Neuro-chirurgia polska, Vol. 34, No. 6, 2000, pp. 56-60.

[128]   P. Jun, N. U. Ko, J. D. English, et al., “Endovascular Treatment of Medically Refractory Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage,” American Journal of Neuroradiology, Vol. 31, No. 10, 2010, pp. 1911-1916. http://dx.doi.org/10.3174/ajnr.A2183

[129]   M. M. Kimball, G. J. Velat and B. L. Hoh, “Critical Care Guidelines on the Endovascular Management of Cerebral Vasospasm,” Neurocritical Care, Vol. 15, No. 2, 2011, pp. 336-341. http://dx.doi.org/10.1007/s12028-011-9600-1

[130]   J. V. Sehy, W. E. Holloway, S. P. Lin, et al., “Improvement in Angiographic Cerebral Vasospasm after Intra-Arterial Verapamil Administration,” American Journal of Neuroradiology, Vol. 31, No. 9, 2010, pp. 1923-1928. http://dx.doi.org/10.3174/ajnr.A2215

[131]   E. Albanese, A. Russo, M. Quiroga, et al., “Ultrahigh-Dose Intraarterial Infusion of Verapamil through an Indwelling Microcatheter for Medically Refractory Severe Vasospasm: Initial Experience,” Journal of Neurosurgery, Vol. 113, No. 4, 2010, pp. 913-922. http://dx.doi.org/10.3171/2009.9.JNS0997

[132]   J. T. Miley, N. Tariq, F. G. Souslian, et al., “Comparison between Angioplasty Using Compliant and Noncompliant Balloons for Treatment of Cerebral Vasospasm Associated with Subarachnoid Hemorrhage,” Neurosurgery, Vol. 69, Suppl. 2, 2011, pp. ons161-ons168.

[133]   A. A. Rabinstein, M. A. Pichelmann, J. A. Friedman, et al., “Symptomatic Vasospasm and Outcomes Following Aneurysmal Subarachnoid Hemorrhage: A Comparison between Surgical Repair and Endovascular Coil Occlusion,” Journal of Neurosurgery, Vol. 98, No. 2, 2003, pp. 319-325. http://dx.doi.org/10.3171/jns.2003.98.2.0319

[134]   A. R. Dehdashti, B. Mermillod, D. A. Rufenacht, et al., “Does Treatment Modality of Intracranial Ruptured Aneurysms Influence the Incidence of Cerebral Vasospasm and Clinical Outcome?” Cerebrovascular Diseases, Vol. 17, No. 1, 2004, pp. 53-60. http://dx.doi.org/10.1159/000073898

[135]   A. J. Goddard, P. P. Raju and A. Gholkar “Does the Method of Treatment of Acutely Ruptured Intracranial Aneurysms Influence the Incidence and Duration of Cerebral Vasospasm and Clinical Outcome?” Journal of Neurology, Neurosurgery & Psychiatry, Vol. 75, No. 6, 2004, pp. 868-872. http://dx.doi.org/10.1136/jnnp.2003.033068

[136]   D. Hanggi and H. J. Steiger, “The Influence of Cisternal and Ventricular Lavage on Cerebral Vasospasm in Patients Suffering from Subarachnoid Hemorrhage: Analysis of Effectiveness,” Acta Neurochirurgica Supplement, Vol. 110, Pt. 2, 2011, pp. 95-98.

[137]   T. Nakagomi, K. Furuya, H. Nagashima, et al., “Surgical Procedure and Results of Cisternal Washing Therapy for the Prevention of Cerebral Vasospasm Following SAH,” Acta Neurochirurgica Supplement, Vol. 110, Pt. 2, 2011, pp. 105-109.

[138]   S. Muehlschlegel, G. Rordorf and J. Sims, “Effects of a Single Dose of Dantrolene in Patients with Cerebral Vasospasm after Subarachnoid Hemorrhage: A Prospective Pilot Study,” Stroke, Vol. 42, No. 5, 2011, pp. 1301-1306. http://dx.doi.org/10.1161/STROKEAHA.110.603159

[139]   M. Y. Tseng, P. J. Hutchinson and P. J. Kirkpatrick, “Interaction of Neurovascular Protection of Erythropoietin with Age, Sepsis, and Statin Therapy Following Aneurysmal Subarachnoid Hemorrhage,” Journal of Neuro-surgery, Vol. 112, No. 6, 2010, pp. 1235-1239. http://dx.doi.org/10.3171/2009.10.JNS09954

[140]   H. C. Lee, C. L. Hsieh, C. C. Chen, et al., “A Pilot Study in Acute Subarachnoid Haemorrhagic Patients after Aneurysm Clipping with Complementary Therapies of Chinese Medicine,” Complementary Therapies in Medicine, Vol. 18, No. 5, 2010, pp. 191-198. http://dx.doi.org/10.1016/j.ctim.2010.07.002

[141]   L. H. Calabrese, D. W. Dodick, T. J. Schwedt and A. B. Singhal, “Narrative Review: Reversible Cerebral Vaso-constriction Syndromes,” Annals of Internal Medicine, Vol. 146, No. 1, 2007, pp. 34-44. http://dx.doi.org/10.7326/0003-4819-146-1-200701020-00007

[142]   A. B. Singhal and R. A. Bernstein, “Postpartum Angiopathy and Other Cerebral Vasoconstriction Syndromes,” Neurocritical Care, Vol. 3, No. 1, 2005, pp. 91-97. http://dx.doi.org/10.1385/NCC:3:1:091

[143]   A. B. Singhal, V. S. Caviness, A. F. Begleiter, E. J. Mark, G. Rordorf and W. J. Koroshetz, “Cerebral Vasoconstriction and Stroke after Use of Serotonergic Drugs,” Neurology, Vol. 58, No. 1, 2002, pp. 130-133. http://dx.doi.org/10.1212/WNL.58.1.130

[144]   D. A. Nowak, S. O. Rodiek, S. Henneken, J. Zinner, R. Schreiner, H. H. Fuchs and H. Topka, “Reversible Segmental Cerebral Vasoconstriction (Call-Fleming Syndrome): Are Calcium Channel Inhibitors a Potential Treatment Option?” Cephalalgia, Vol. 23, No. 3, 2003, pp. 218-222. http://dx.doi.org/10.1046/j.1468-2982.2003.00507.x

[145]   A. B. Singhal, “Cerebral Vasoconstriction Syndromes,” Topics in Stroke Rehabilitation, Vol. 11, No. 2, 2004, pp. 1-6. http://dx.doi.org/10.1310/ATK7-QTP7-7NE2-5G8X

[146]   S. P. Chen, J. L. Fuh, J. F. Lirng, F. C. Chang and S. J. Wang, “Recurrent Primary Thunderclap Headache and Benign CNS Angiopathy: Spectra of the Same Disorder?” Neurology, Vol. 67, No. 12, 2006, pp. 2164-2169. http://dx.doi.org/10.1212/01.wnl.0000249115.63436.6d

[147]   A. Ducros, U. Fiedler, R. Porcher, M. Boukobza, C. Stapf and M. G. Bousser, “Hemorrhagic Manifestations of reversible Cerebral Vasoconstriction Syndrome: Frequency, Features, and Risk Factors,” Stroke, Vol. 41, No. 11, 2010, pp. 2505-2011. http://dx.doi.org/10.1161/STROKEAHA.109.572313

[148]   S. P. Chen, J. L. Fuh, F. C. Chang, J. F. Lirng, B. C. Shia and S. J. Wang, “Transcranial Color Doppler Study for Reversible Cerebral Vasoconstriction Syndromes,” Annals of Neurology, Vol. 63, No. 6, 2008, pp. 751-757. http://dx.doi.org/10.1002/ana.21384

[149]   S. P. Chen, J. L. Fuh and S. J.Wang, “Reversible Cerebral Vasoconstriction Syndrome: An Under-Recognized Clinical Emergency,” Therapeutic Advances in Neurological Disorders, Vol. 3, No. 3, 2010, pp. 161-171. http://dx.doi.org/10.1177/1756285610361795

[150]   M. Elstner, J. Linn, S. Müller-Schunk and A. Straube, “Reversible Cerebral Vasoconstriction Syndrome: A Complicated Clinical Course Treated with Intra-Arterial Application of Nimodipine,” Cephalalgia, Vol. 29, No. 6, 2009, pp. 677-682. http://dx.doi.org/10.1111/j.1468-2982.2008.01768.x

[151]   M. Klein, G. Fesl, H. W. Pfister, A. Straube, H. Brück-mann, L. A. Hoffmann and T. Pfefferkorn, “Intra-Arterial Nimodipine in Progressive Postpartum Cerebral Angiopathy,” Cephalalgia, Vol. 29, No. 2, 2009, pp. 279-282. http://dx.doi.org/10.1111/j.1468-2982.2008.01728.x

[152]   M. Bouchard, S. Verreault, J. L. Gariépy and N. Dupré, “Intra-Arterial Milrinone for Reversible Cerebral Vaso- constriction Syndrome,” Headache, Vol. 49, No. 1, 2009, pp. 142-145. http://dx.doi.org/10.1111/j.1526-4610.2008.01211.x